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Abstract
Valproic acid, first manufactured as an anticonvulsant, is commonly used to treat both
neurological and psychiatric conditions. A rare and deadly side effect of this medication is
hyperammonemia, presenting as lethargy, confusion, seizure, and, ultimately, coma. In rare
circumstances, hyperammonemia can be recurrent and devastating, especially in patients with
an underlying N-acetyl glutamate synthase (NAGS) deficiency, as the valproic acid can enhance
this enzyme deficiency and inhibit the conversion of ammonia into urea in the liver. For these
subtypes of patients, the United States Food and Drug Administration (US FDA) has recently
approved carglumic acid, a medication that can act as a scavenger by effectively increasing the
levels of NAGS, ultimately enhancing the conversion of ammonia to urea. In our case report, we
have mentioned a patient with treatment-resistant bipolar disorder, who presented with
elevated ammonia levels secondary to valproic acid treatment. Valproic acid was the only drug
that was effective in his case, so we initiated therapy to reduce his elevated ammonia levels.
After a thorough evaluation, we found the patient had a genetic NAGS deficiency. Carglumic
acid was initiated and proved efficacious in our patient.
Categories: Internal Medicine, Neurology, Psychiatry
Keywords: valproic acid, carglumic acid, carbaglu, viha, hyper ammonia, hyperammonemia
Introduction
Valproic acid (VA) was first manufactured in 1881 and has been used therapeutically since 1962
[1]. VA is commonly used in the treatment of certain neurological and psychiatric conditions
like epilepsy, migraine, bipolar disorder, and borderline personality disorder, and VA is
sometimes used to treat patients with alcohol withdrawal. VA is also very effective in the
reduction of psychotic symptoms like agitation and aggression in patients with traumatic brain
injuries [2-3]. VA is generally considered safe and is part of the World Health Organization’s
(WHO's) list of essential medicines [4]. Despite its safety profile, VA’s common side effects
include dry mouth, nausea, and vomiting. One of the rare, but potentially life-threatening side
effect of VA is hyperammonemia [5]. VA-induced hyperammonemia usually presents as
lethargy, vomiting, or any focal neurologic deficit [6] and is usually due to VA’s toxic
metabolite-induced inhibition of N-acetyl glutamate synthetase (NAGS), a rate-limiting
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enzyme of the urea cycle. This inhibition leads to increased ammonia levels [7]. VA-induced
hyperammonemia can be recurrent and devastating, especially in patients with a genetic NAGS
deficiency (NAGSD). We present a case of a patient diagnosed with recurrent hyperammonemia
due to VA and describe the successful treatment of that patient.
Case Presentation
A 23-year-old African American man with a history of bipolar disorder presented to the
Comprehensive Psychiatric Emergency Program with an altered mental state and copious
vomiting. As per the emergency protocols, two large-bore (16 gauge) intravenous
cannulas were placed, and a standard saline infusion was started to treat the patient’s
descending blood pressure. The initial examination revealed a Glasgow Coma Scale Score of 15
(eyes, 4; verbal, 5; and motor, 6), and a quick neurological exam failed to reveal any deficits in
the extremities. The patient exhibited normal muscle strength, deep tendon reflexes, and
cranial nerve function. His gait could not be assessed due to fatigue and the emergency
condition. Table 1 presents the clinical laboratory values at admission.
Analyte Result
Hemoglobin 121 g/L
Platelet count 170 x109/L
Peripheral blood smear Elevated neutrophil count






Stool culture results Negative
Urine culture results Negative
Blood culture results Negative
TABLE 1: Clinical laboratory values on presentation
Abbreviations: HCO3, bicarbonate; pCO2, partial pressure of carbon dioxide.
The patient’s medication log stated he was currently taking VA 1500 mg daily, split into a 500-
mg morning dose and a 1000-mg evening dose. His medical records revealed this VA dose was
initiated four months prior after trials with other medications had failed due to adverse effects
(diarrhea due to lithium). After starting VA, the patient was monitored via follow-up
examinations in the clinic on a monthly basis. On his second-month follow-up visit, the patient
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reported concerns of weakness and fatigue. Laboratory tests revealed elevated ammonia and
VA levels. At this time, the patient was diagnosed with VA-induced hyperammonemia. The VA
treatment was stopped, and the patient was started on lactulose syrup and lamotrigine. We
monitored the patient weekly. After his third weekly visit, he reported concerns of worsening of
manic symptoms and severe bullae and rashes on his chest. The lamotrigine was stopped and
manic symptoms recurred, leading to reinstating the VA treatment with weekly follow-up
monitoring. His ammonia levels were elevated on all follow-up visits. A daily combination of
lactulose syrup and levocarnitine was added to the treatment regimen in each weekly visit, but
his ammonia levels continued to rise.
The patient presented with neurological symptoms with vomiting. Given his medical records,
he was diagnosed with VA-induced hyperammonemic encephalopathy. His serum ammonia
level was 68 µmol/L (reference range, 11 to 32 µmol/L). His serum VA level was within the
reference range. After successful symptomatic control, the patient tested positive for an
underlying genetic NAGSD. Therefore, we concluded this patient’s exaggerated response to VA
in developing hyperammonemia was related to his underlying NAGSD. He was discharged from
the inpatient facility with a daily dosing of 1500 mg VA and 800 mg carglumic acid.
Discussion
VA is a short, branched-chain fatty acid that undergoes beta-oxidation in the mitochondria of
hepatocytes and is converted into the toxic metabolite valproyl CoA. This metabolite depletes
N-acetyl glutamate by the inhibition of N-acetyl glutamate synthetase, a rate-limiting enzyme
[7]. VA can effectively treat a variety of neurologic and psychiatric conditions and is generally
considered to be safe within a broad therapeutic range [8]. However, in patients with an
underlying genetic deficiency of NAGS, VA can cause recurrent hyperammonemia, a fatal
condition that can present as any focal neurologic deficit. An inherited NAGSD is an extremely
rare urea cycle disorder with an estimated incidence of less than one in 2,000,000, caused by
recessive mutations in the NAGS gene. Mitochondrial NAGS synthesizes the allosteric activator
of the first enzyme of the urea cycle, carbamoyl phosphate synthetase 1 (CPS1). Clinically and
biochemically, NAGSD is indistinguishable from a CPS1 deficiency, and common biochemical
features include increased amounts of plasma ammonia and glutamine, reduced plasma
citrulline, and normal or low levels of urinary orotic acid. NAGS enzyme assays are problematic,
as they necessitate a liver specimen, so molecular analysis is the gold standard test for
confirming NAGSD [9-10].
VA-induced hyperammonemia can present with normal or elevated drug levels [11]. We found
multiple studies reporting the association of high ammonia levels with the use of VA. Twenty
percent to 50% of patients who were prescribed VA had elevated ammonia levels [12]. A VA-
induced rise in ammonia levels can be asymptomatic or clinically symptomatic. Physicians
should rule out any underlying causes of elevated ammonia levels such as urea cycle disorders
or drug-induced spikes. The diagnosis of VA-induced hyperammonemia can be made by a
combination of clinical symptoms, elevated ammonia levels, normal or elevated VA levels, and
urea cycle enzyme assay levels, as shown in Table 2.








 Focal neurological deficits 
 Coma
Diagnosis  
Serum Ammonia Level Elevated (reference range, 11–32 µmol/L)
Serum Valproic Acid Level Can be in the reference range or elevated (reference range, 346–693 µmol/L)
Differentials  
 Rule out urea cycle disorders
TABLE 2: Summary of diagnosis criteria of VA-induced hyperammonemia
Abbreviations: VA, valproic acid.
For both asymptomatic and symptomatic ammonia level elevations, consider a discontinuation
of the medication and add alternative medication to control psychiatric symptoms [13]. VA-
induced hyperammonemia and how NAGSD affects the whole urea cycle is summarized in
Figure 1 [14].
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FIGURE 1: Summary of how NAGSD affects the urea cycle in
VA-induced hyperammonemia
Abbreviations: NAGSD, N-acetyl glutamate synthase deficiency; VA, valproic acid; CACT,
carnitine-acylcarnitine translocase; CAT, chloramphenicol acetyltransferase; CoA, coenzyme
A; NAGS, N-acetyl glutamate synthase; CPS, carbamoyl phosphate synthetase; ATP, adenosine
triphosphate; ORC, ornithine carrier protein; ASL, argininosuccinic lyase; ASS,
argininosuccinate synthase.
In patients with a congenital deficiency of NAGS, NAGS inhibition by VA is more pronounced
and can cause recurrent hyperammonemia in patients taking VA. The US FDA approved
carglumic acid for use in patients with an inherited deficiency in pediatric or adult patients.
Carglumic acid is a great therapeutic option if the patient is only responsive to VA for
psychiatric symptoms because the options for alternative medication are limited. Carglumic
acid is generally safe and efficacious in these patients, but in some patients, it can cause
adverse gastrointestinal effects like nausea, vomiting, and abdominal pain. Figure 2
summarizes the management of a patient with VA-induced hyperammonemia.
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FIGURE 2: The management of a patient with VA-induced
hyperammonemia
Abbreviation: VA, valproic acid.
Conclusions
Congenital urea cycle disorders should be ruled out in diagnosing VA-induced
hyperammonemia. An early recognition of elevated ammonia levels can lead to a decrease in
mortality or morbidity issues.
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